MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma

BACKGROUND: Determining failure to anti-angiogenic therapy in recurrent glioblastoma (GBM) (rGBM) remains a challenge. The purpose of the study was to assess treatment response to bevacizumab-based therapy in patients with rGBM using MR spectroscopy (MRS). METHODS: We performed longitudinal MRI/MRS...

Descripción completa

Detalles Bibliográficos
Autores principales: Talati, Pratik, El-Abtah, Mohamed, Kim, Daniel, Dietrich, Jorg, Fu, Melanie, Wenke, Michael, He, Julian, Natheir, Sharif N, Vangel, Mark, Rapalino, Otto, Vaynrub, Anna, Arrillaga-Romany, Isabel, Forst, Deborah A, Yen, Yi-Fen, Andronesi, Ovidiu, Kalpathy-Cramer, Jayashree, Rosen, Bruce, Batchelor, Tracy T, Gonzalez, R Gilberto, Gerstner, Elizabeth R, Ratai, Eva-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193903/
https://www.ncbi.nlm.nih.gov/pubmed/34131648
http://dx.doi.org/10.1093/noajnl/vdab060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193903/
https://www.ncbi.nlm.nih.gov/pubmed/34131648
http://dx.doi.org/10.1093/noajnl/vdab060

Ejemplares similares